Tamoxifen 20 - Ice Pharmaceuticals

Tamoxifen citrate, the active ingredient in Nolvadex, has its origins in early 1960s British pharmaceutical research. Though originally explored as a contraceptive, its significant impact on estrogen pathways led to its adoption as a treatment for breast cancer. It was FDA-approved in 1977 and soon became the standard therapy for hormone-responsive tumors. Outside of oncology, Tamoxifen gained a second life among steroid users aiming to control estrogenic side effects and assist with post-cycle hormone normalization.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tamoxifen 20 by Ice Pharmaceuticals, consult with your doctor or healthcare professional.